Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/79540
COMPARTIR / EXPORTAR:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorPilar-Cuéllar, Fuencisla-
dc.contributor.authorMadureira, Rebeca-
dc.contributor.authorDíaz, Álvaro-
dc.contributor.authorPazos, Ángel-
dc.contributor.authorValdizán, Elsa M.-
dc.date.accessioned2013-07-12T10:04:47Z-
dc.date.available2013-07-12T10:04:47Z-
dc.date.issued2009-
dc.identifier.citation10ª SEIC (2009)-
dc.identifier.urihttp://hdl.handle.net/10261/79540-
dc.descriptionTrabajo presentado a la 10ª Reunión anual de la Sociedad Española de Investigación sobre Cannabinoides celebrada en Santander del 26 al 28 de noviembre de 2009.-
dc.description.abstractThe endogenous cannabinoid system is involved in the pathophysiology of depression: an increase of CB1 receptor density and functionality is present in animal models of depression, such as olfactory bulbectomy; and increased endocannabinoid levels have been reported in frontal cortex of suicide victims. On the other hand, several intracellular pathways involved in cell proliferation and fate of adult hippocampal stem/progenitor cells (AHPs), including ß-catenin, AKT/PKB and BDNF, are modulated by antidepressants: fluoxetine (SSRI) treatment has been reported to induce an increase in AKT/PKB pathway activity, cytosolic ß-catenin levels and BDNF expression. Here we study the modulation of the effects of fluoxetine treatment on these intracellular pathways in hippocampus by the coadministration of the cannabinoid agonist [delta]9-tetrahydrocannabinol (THC). We measured ß-catenin, AKT and BDNF protein levels by Western blot in male Sprague Dawley rats following the chronic administration of THC (10 mg/kg/day, 21 days; i.p.), fluoxetine (10 mg/kg/day, 21 days; p.o.), or the combination of both THC+fluoxetine. In OB+vehicle group a clear but not significant reduction of ß-catenin, AKT and BDNF protein levels vs sham+vehicle. THC and fluoxetine treatments produced an increase of ß-catenin, AKT and BDNF protein levels in hippocampal homogenates (p<0,05). A significantly higher effect was observed in the group corresponding to the association THC+fluoxetine (p<0,01) for these three markers. Thus we conclude that 1) in the olfactory bulbectomy model of depression there is a tendency to the reduction of a series of proliferative pathways in the hippocampus, such as ß-catenin, AKT/PKB and BDNF; and 2) both fluoxetine and THC treatments reverse these depression-associated neuroplastic changes, suggesting the implication of the cannabinoid system in the therapeutic antidepressant response.-
dc.description.sponsorshipSupported by Ministerio de Ciencia e Innovación (SAF07-61862) and Plan Nacional de Drogas (2006).-
dc.language.isoeng-
dc.rightsclosedAccess-
dc.titleNeuroplasticity pathways -ß-catenin, AKT/PKB, BDNF- in an animal model of depression: influence of chronic F9-tetrahydrocannabinol administration-
dc.typecomunicación de congreso-
dc.date.updated2013-07-12T10:04:47Z-
dc.description.versionPeer Reviewed-
dc.type.coarhttp://purl.org/coar/resource_type/c_5794es_ES
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairetypecomunicación de congreso-
Aparece en las colecciones: (IBBTEC) Comunicaciones congresos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

Page view(s)

332
checked on 21-may-2024

Download(s)

37
checked on 21-may-2024

Google ScholarTM

Check


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.